Ta Associates
TA Associates is a global private equity firm founded in 1968. It states that it invests $150-$600 million in profitable growth companies and is comfortable taking minority or majority positions.
What stands out about Ta Associates
TA Associates describes a growth-oriented investment approach across technology, business services, financial services and healthcare. Its stated equity-investment range is $150-$600 million, and it may provide shareholder liquidity, growth capital or acquisition financing through minority or majority investments.[1][2][3][4][5]
What does Ta Associates invest in?
TA Associates Management, L.P. is a global private equity firm founded in 1968 and operating under the TA Associates brand. TA says it partners with high-quality companies to accelerate growth using industry expertise, strategic resources and a global network.
TA states that its portfolio includes more than 140 companies across technology, business services, financial services and healthcare.[1][3]
TA describes a collaborative investment approach. It generally works with management on key objectives at the board level while leaving day-to-day operations to the company.
TA states that its equity capital may be used for shareholder liquidity, working capital for growth and financing acquisitions. It also describes itself as a long-term, patient growth investor, with a holding period that has averaged more than 5 years over the past 15 years.[4]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
Published criteria: TA states that its equity investments can range from $150-$600 million. It focuses on scaling growth in profitable companies, is comfortable investing for minority or majority positions, and states that its portfolio includes more than 140 companies.[2][4]
What should a business owner evaluate before considering a transaction with Ta Associates?
An owner evaluating TA should clarify the proposed ownership position, governance rights and the balance between shareholder liquidity, growth investment and acquisition financing. TA’s stated board-level partnership model also makes the intended division between board involvement and day-to-day management an important point to define.
Owners may also wish to establish the expected investment horizon for the specific transaction, the TA operating resources and sector professionals assigned to the company, any proposed acquisition strategy, the leverage profile and approval process, and the legal TA entity and fund vehicle making the investment.[4]
What ownership position and governance rights would TA seek for this company
What portion of the proposed capital would fund shareholder liquidity versus growth investment or acquisitions
What is the expected investment horizon for this specific transaction, and how does it compare with TA’s stated average holding period of more than 5 years
What companies does Ta Associates target?
TA states that its equity investments can range from $150-$600 million. It focuses on scaling growth in profitable companies and is comfortable investing for minority or majority positions.[2][4]
TA identifies four defined sectors of focus: technology, business services, financial services and healthcare.[4]
TA states that its international team collaborates across North America, Europe and Asia. Its official global-offices page lists offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong.[4][6]
TA describes a global investment platform and states that its equity capital may finance acquisitions. Its public transaction record includes the acquisition of a majority stake in FD Technologies’ KX business, with existing shareholders retaining a minority interest.
The sources cited for this profile do not establish a standardized platform-versus-add-on policy.[4][11]
TA’s official portfolio directory identifies companies by sector, region and current or past status. Examples identified as current companies include 8am, Accion Labs, Advantive Health, Advantive, Aeris, FGE NexantECA, FinQuery, PowerGEM and WorkWave.[1][5]
TA announced a strategic investment in Too Lost on March 16, 2026, a strategic partnership with The Forge Companies on February 2, 2026, and a strategic growth investment in iBase-t on March 31, 2026.
On May 8, 2025, TA announced an all-cash offer to acquire FD Technologies, valuing the company at approximately £570 million. A July 23, 2025 announcement states that TA acquired a majority stake in FD Technologies’ KX business, with existing shareholders retaining a minority interest.[7][8][9][10][11]
What is not clear from Ta Associates's public investment criteria?
The official TA portfolio directory does not publish a transaction value, acquisition date or consideration amount for each listed portfolio company on that page.
The official approach page does not publish a universal fund-level minimum investment amount, fund-level ownership target or standardized transaction fee schedule; it publishes an equity-investment range and ownership-position description instead.[4][5]
Questions to ask when evaluating Ta Associates as a buyer or investment partner
What ownership position and governance rights would TA seek for this company?
What portion of the proposed capital would fund shareholder liquidity versus growth investment or acquisitions?
What is the expected investment horizon for this specific transaction, and how does it compare with TA’s stated average holding period of more than 5 years?
Which TA operating resources and sector professionals would support the company?
What is the proposed acquisition strategy, leverage profile and approval process, and which legal TA entity and fund vehicle would make the investment?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Investment strategy
- Investment approach
- Transaction / portfolio evidence
- Geography / market coverage
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Structure / regulatory context
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.